EUCTR2018-000532-94-IT进行中(未招募)1 期
Optimal duration of dual antiplatelet therapy in patients treated by endovascular revascularization of the superficial femoral artery (Dual Antiplatelet Therapy-Superficial Femoral Artery, DAPT-SFA) - Optimal duration of dual anti-platelet therapy in patients undergoing endovascular revascularization
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO0 个研究点目标入组 78 人开始时间: 2020年11月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Have given written informed consent to participate
- •Be aged 18 years and over
- •Be affected by lower limbs PAOD staged 2-5 according to Rutherford classification and lesions of the SFA
- •Have undergone a successful endovascular revascularization of the SFA as documented by the intra-operative angiography
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 48
排除标准
- •-Life expectancy < 12 months
- •-Contraindication to DAPT or ASA/clopidogrel assumption (Hypersensitivity to the basic principle or excipients, history of acute asthma or angioneurotic edema associated with drug assumption, peptic ulcer and/or gastro-intestinal haemorrhage in acute phase or in medical records, or other kinds of haemorrhage (e.g. cerebrovascular bleeding), haemorrhagic diathesis, haemostasis disturbances (e.g. Thrombocytopenia or haemophilia), severe cardiac failure, severe liver failure, severe CKF (GFR<30ml/h), therapy with methotrexate at dosage > 15 mg per week)
- •-Participants to a clinical trial consisting in administration of an experimental drug within 30 days or 5 half-lives of the drug under investigation.
- •-Patients under anticoagulant therapy
- •-History of allergies to ASA and/or clopidogrel
- •-Lack of written informed consent by the patients
- •-Unwillingness, impossibility or incapability to respect the study protocol for any reason
- •-CKF under haemodialytic treatment, because it can affect the patency rate of the lumen bias the results on such a small-sized sample)
- •-Pregnant women
研究者
相似试验
进行中(未招募)
不适用
Optimal duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms: A prospective randomized multicenter trialDiseases of the circulatory systemKCT0006651Seoul National University Bundang Hospital528
已完成
不适用
ShorT and OPtimal duration of Dual AntiPlatelet Therapy studycoronary artery diseaseJPRN-UMIN000008878Kyoto University Hospital1,500
进行中(未招募)
4 期
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-3 studyIschemic heart disease, stable angina, myocardial infarctionJPRN-jRCTs052200114Ono Koh6,000
进行中(未招募)
4 期
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-2 study for patients with ACSJPRN-jRCTs052180193Ono Koh3,000
招募中
3 期
To Compare Longterm Single versus Dual Antiplatelet Therapy In Ischemic Stroke due to atherosclerotic narrowing of blood vessel in the brain.CTRI/2022/01/039445Dr Rohit Bhatia
